DOTA like compounds acts as chelating agents that binds radiometals and links them to a targeting molecule such as an antibody, peptide, or other vector.
The radiometal provides the signal for imaging (PET/SPECT) or the therapeutic effect, while the targeting molecule directs the compound to the biological site of interest.
By forming a highly stable complex, DOTA ensures that the radionuclide remains bound during circulation, enabling precise targeting and reliable in vivo performance.
The efficiency of the system relies on the optimal combination of chelator (DOTA), radiometal, and targeting vector, as well as a well-controlled conjugation strategy.